Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Neoplasm Metastasis
Interventions: DRUG: SKI-606 (Bosutinib)
Sponsor: Pfizer